The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases

BACKGROUND: More than half of the metastatic breast cancer patients with brain metastases (BCBM) are HER-2 negative, and the prognosis of HER2-negative BCBM is dismal. But few clinical trials have investigated systemic therapies for this subgroup of patients. METHODS: This real-world study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xuelian, Bai, Xue, Xie, Xiaofeng, Huang, Jiayi, Chen, Liping, Song, Lin, Lan, Xiaofeng, Zhang, Qiuyi, Guo, Jinfeng, Du, Caiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236966/
https://www.ncbi.nlm.nih.gov/pubmed/37260331
http://dx.doi.org/10.1080/07853890.2023.2218647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236966/
https://www.ncbi.nlm.nih.gov/pubmed/37260331
http://dx.doi.org/10.1080/07853890.2023.2218647

Ejemplares similares